Alkermes plc (ALKS)
NASDAQ:ALKS
Want to see ALKS full AI Analyst Report?
ALKS Stock Chart & Stats
$34.53
-$0.20(-0.70%)
At close: 4:00 PM EST
$34.53
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $42.87
Previous CloseN/A
Volume176.14K
Average Volume (3M)2.06M
Market Cap
$6.89B
Enterprise Value$8.26B
Total Cash (Recent Filing)$511.86M
Total Debt (Recent Filing)$1.58B
Price to Earnings (P/E)45.0
Beta0.82
Next Earnings
Jul 29, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding166,675,810
10 Day Avg. Volume2,110,133
30 Day Avg. Volume2,056,820
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue5.29
Enterprise Value/Gross Profit6.10
Enterprise Value/Ebitda29.89
Forecast
1Y Price Target
$45.60Price Target Upside32.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$1.81B
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsAlkermes' ~85.8% gross margin reflects a durable cost structure tied to specialized long‑acting injectable manufacturing and branded products. High gross margins support scalable cash generation and reinvestment into R&D and commercialization over the medium term, insulating core profitability versus modest revenue swings.
Strong Proprietary Product Momentum / LUMRYZ LaunchConsistent 38% YoY proprietary product growth and an early LUMRYZ launch with thousands of patients indicate durable commercial execution and portfolio diversification. New product traction reduces concentration risk, creates recurring revenue streams, and strengthens long‑term market position in neuroscience.
Positive Cash Generation And Adjusted EBITDA BeatPositive operating cash flow and FCF, along with an adjusted EBITDA beat, demonstrate ongoing internal cash generation that can service debt, fund pipeline programs, and support integration. Even with weaker momentum, sustained positive cash flow is a durable foundation for capital allocation over coming quarters.
Bears Say
Material Rise In LeverageA sharp increase in debt to ~$1.58B materially raises financial risk and reduces flexibility. Higher leverage constrains strategic optionality, increases interest and covenant sensitivity, and requires sustained cash generation or asset sales to deleverage — a multi‑quarter structural headwind to balance‑sheet resilience.
Weaker Net Margin And FCF MomentumDeclining net margin and a >50% drop in free cash flow indicate deteriorating bottom‑line conversion and cash quality. This reduces internal funding capacity for R&D and debt paydown, making the company more dependent on operating improvements or external financing to sustain strategic investments over the next several quarters.
Higher Operating Costs And Inventory Step‑up PressureElevated R&D and SG&A—driven by Phase III programs and acquisition integration—plus inventory step‑up that inflates COGS, create persistent margin pressure. These structural cost increases could compress operating leverage and delay full profit conversion from revenue growth until integration and pipeline investments normalize.
Alkermes News
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $25.16 and its highest was $42.87 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $6.89B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Jul 29, 2026 which is in 55 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on May 05, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.146.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc does not currently pay dividends.
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is -0.01.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 166,675,810 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went up 6.087%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.60 (32.06% Upside)
$45.60 (32.06% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 240.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $687.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.05%
12-Months-Change
Fundamentals
Return on Equity
8.82%
Trailing 12-Months
Asset Growth
104.52%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum, sizable year-over-year revenue growth (+38% for proprietary products), an encouraging early LUMRYZ launch with meaningful sales and patient growth, a material adjusted EBITDA beat, and clear pipeline progress with Phase III initiation and multiple new programs underway. Offsetting factors include a GAAP net loss and negative GAAP EBITDA in the quarter, elevated R&D and SG&A as programs scale and integration costs are realized, increased leverage and near-term margin pressure from inventory step-up and widening gross-to-net. On balance, the positives (revenue growth, LUMRYZ contribution, adjusted EBITDA beat, improved purchase price accounting and an expanding orexin pipeline) meaningfully outweigh the near-term financial and execution headwinds.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$45.60
▲(32.06% Upside)
Technical Analysis
Ownership Overview
1.43% Insiders
25.89% Mutual Funds
29.61% Other Institutional Investors
10.36% Public Companies and
Individual Investors